- - - Angion scientists also present research advancing the scientific understanding of proteinuric and polycystic kidney disease SAN FRANCISCO – November 11, 2019 – Angion Biomedica Corp. (Angion), a clinical stage biopharmaceutical company developing a first-in-class therapy to treat acute kidney injury, presented five abstracts...

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] - - -ANG-3777 shows improved short- and long-term graft function with a positivesafety profile in a Phase 2 study- - -New data support company’s ongoing Phase 3 study UNIONDALE, N.Y. – November 7, 2019 – Angion Biomedica Corp....

UNIONDALE, N.Y. October 14, 2019 --- Angion Biomedica Corp., a clinical stage biopharmaceutical company developing a first-in-class therapy targeting acute kidney injury, today announced the appointment of several members to its management team, including Mr. Kevin Norrett as senior vice president and chief commercial officer, Dr. Tracy Mayne as vice...

Five additional abstracts accepted as poster presentations throughout Kidney Week 2019 UNIONDALE, N.Y. – October 11, 2019 – Angion Biomedica Corp. (Angion), a clinical stage biopharmaceutical company developing a first-in-class therapy to treat acute kidney injury, today announced that it will be presenting new long-term follow-up...

HONG KONG, SHANGHAI, and UNIONDALE, N.Y. November 12th, 2018 – (PRNewswire)  –  Angion Biomedica and Sinovant Sciences today announced a collaboration and license agreement for BB3, Angion’s investigational small molecule mimetic of hepatocyte growth factor (HGF), in the People’s Republic of China, Hong Kong, Macau,...